MALČÍKOVÁ, Jitka, Šárka PAVLOVÁ, Barbara VONKOVÁ, Jana KOTAŠKOVÁ, Lenka RADOVÁ, Karla PLEVOVÁ, Marcela ŽENATOVÁ, Jakub HYNŠT, Barbara DVOŘÁČKOVÁ, Anna PANOVSKÁ, Yvona BRYCHTOVÁ, Boris TICHÝ, Nikola TOM, Karol PÁL, Jiří MAYER, Michael DOUBEK and Šárka POSPÍŠILOVÁ. Minor-clone TP53 mutations in CLL patients entering first-line treatment: clonal evolution and clinical impact. In XVIII. International Workshop on CLL (iwCLL), Edinburgh, Spojené království. 2020. ISSN 1042-8194.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Minor-clone TP53 mutations in CLL patients entering first-line treatment: clonal evolution and clinical impact.
Authors MALČÍKOVÁ, Jitka (203 Czech Republic, belonging to the institution), Šárka PAVLOVÁ (203 Czech Republic, belonging to the institution), Barbara VONKOVÁ (203 Czech Republic, belonging to the institution), Jana KOTAŠKOVÁ (203 Czech Republic, belonging to the institution), Lenka RADOVÁ (203 Czech Republic, belonging to the institution), Karla PLEVOVÁ (203 Czech Republic, belonging to the institution), Marcela ŽENATOVÁ (203 Czech Republic), Jakub HYNŠT (203 Czech Republic, belonging to the institution), Barbara DVOŘÁČKOVÁ (203 Czech Republic, belonging to the institution), Anna PANOVSKÁ (203 Czech Republic), Yvona BRYCHTOVÁ (203 Czech Republic), Boris TICHÝ (203 Czech Republic, belonging to the institution), Nikola TOM (203 Czech Republic, belonging to the institution), Karol PÁL (703 Slovakia, belonging to the institution), Jiří MAYER (203 Czech Republic), Michael DOUBEK (203 Czech Republic, belonging to the institution) and Šárka POSPÍŠILOVÁ (203 Czech Republic, belonging to the institution).
Edition XVIII. International Workshop on CLL (iwCLL), Edinburgh, Spojené království, 2020.
Other information
Original language English
Type of outcome Conference abstract
Field of Study 30204 Oncology
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 3.280
RIV identification code RIV/00216224:14740/20:00114040
Organization unit Central European Institute of Technology
ISSN 1042-8194
UT WoS 000534385400155
Keywords in English Minor-clone TP53; CLL patients
Tags rivok
Tags International impact
Changed by Changed by: Mgr. Pavla Foltynová, Ph.D., učo 106624. Changed: 16/3/2021 19:24.
Abstract
Aims • To assess the risk of clonal expansion of minor-clone TP53 mutations • To evaluate the clinical impact of TP53 mutations with different variant allele frequencies (VAFs) ...in patients entering first-line treatment
Links
GA19-11299S, research and development projectName: Úloha transpozibilních elementů u hematologických malignit
Investor: Czech Science Foundation
GA19-15737S, research and development projectName: Alternativní mechanismy deregulace p53 dráhy u chronické lymfocytární leukémie
Investor: Czech Science Foundation, Alternative mechanisms of deregulation of the p53 pathway in chronic lymphocytic leukemia
MUNI/A/1105/2018, interní kód MUName: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit VI (Acronym: VýDiTeHeMA VI)
Investor: Masaryk University, Category A
NV19-03-00091, research and development projectName: Komplexní prognostický a prediktivní panel pro pacienty s chronickou lymfocytární leukémií: nástroj sekvenování nové generace vhodný pro klinickou praxi i studium genetického pozadí průběhu choroby
Investor: Ministry of Health of the CR
PrintDisplayed: 29/5/2024 18:51